SEC Form 4 · accession 0001213900-26-103536
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Miriam Kidron
Officer — Chief Scientific Officer · Director
Period of report
Sep 24, 2026
Accepted (ET)
Sep 25, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 24, 2026 | A | 208,125 | — | A | 1,341,263 | D | |
| Common StockF2 | Sep 24, 2026 | A | 209,291 | — | A | 1,550,554 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1,F3 | $3.16 | Sep 24, 2026 | D | 104,000 | D | — | Sep 11, 2029 | Common Stock | 104,000 | 0 | D |
| Stock option (right to buy)F1,F4 | $4.80 | Sep 24, 2026 | D | 100,000 | D | — | Jan 8, 2030 | Common Stock | 100,000 | 0 | D |
| Stock option (right to buy)F1,F5 | $7.77 | Sep 24, 2026 | D | 69,999 | D | — | Jun 30, 2027 | Common Stock | 69,999 | 0 | D |
| Stock option (right to buy)F1,F6 | $8.14 | Sep 24, 2026 | D | 47,000 | D | — | Jan 31, 2028 | Common Stock | 47,000 | 0 | D |
| Stock option (right to buy)F1,F7 | $10.40 | Sep 24, 2026 | D | 100,000 | D | — | Feb 3, 2031 | Common Stock | 100,000 | 0 | D |
| Stock option (right to buy)F1,F8 | $13.89 | Sep 24, 2026 | D | 72,000 | D | — | Jan 3, 2032 | Common Stock | 72,000 | 0 | D |
Explanation of responses
- F1On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
- F2On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.
- F3The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.
- F4The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
- F5The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019.
- F6The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.
- F7The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
- F8The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.